Finasteride Cost in Oregon 2026

What Does Finasteride Actually Cost in Oregon Right Now?

Generic finasteride tablets cost approximately $12 per month at Oregon retail pharmacies in 2026 when paid out-of-pocket, compared with the Merck brand (Propecia/Proscar) list price of around $85 per month. That price gap exists because multiple manufacturers now produce FDA-approved generic versions, which are therapeutically equivalent to the brand. GoodRx data consistently show Oregon-area pharmacies including Costco, Fred Meyer, and Rite Aid pricing 30-tablet supplies of generic finasteride 1 mg between $9 and $18 depending on chain and coupon applied.

The 5 mg tablet used for benign prostatic hyperplasia (BPH) follows a similar pattern. Generic finasteride 5 mg runs $15 to $25 per month cash-pay at most Oregon outlets. Many clinicians and patients use a pill-splitter to halve 5 mg tablets for the 2.5 mg or 1.25 mg off-label AGA doses, which can push the effective monthly cost below $10. That practice carries no FDA endorsement but is widely discussed in the dermatology literature.

Finasteride works by inhibiting 5-alpha-reductase type II, blocking conversion of testosterone to dihydrotestosterone (DHT). DHT is the primary androgen driving both male-pattern hair loss and prostate enlargement, and suppressing it by roughly 65-70% is the pharmacological basis for finasteride's effects. Kaufman et al. (J Am Acad Dermatol 1998, N=1,553) demonstrated statistically significant increases in hair count and patient-assessed improvement over 48 weeks at the 1 mg dose, with the study stating: "Finasteride 1 mg/day was effective in men with male-pattern hair loss, with significant increases in hair count documented at 12 and 24 months." [1]

Oregon has no state-level price control on prescription drugs beyond federal Medicaid rebate rules, so pharmacy-level cash prices vary by a few dollars across Portland metro, Eugene, Salem, and rural areas. Using a free discount card (GoodRx, RxSaver, NeedyMeds) at the point of sale typically brings the price to the lower end of that range regardless of ZIP code.

Oregon Medicaid (OHP) Coverage for Finasteride

Oregon Health Plan covers finasteride, but the coverage pathway depends on the diagnosis code. For BPH (ICD-10 N40.x), finasteride 5 mg is on the OHP Preferred Drug List with prior authorization (PA) required. The Oregon Medicaid Preferred Drug List, maintained by the Oregon Pharmacy and Therapeutics Committee, classifies finasteride as a covered preferred agent for BPH when clinical criteria are met. The PA process typically asks the prescriber to document prostate symptom severity using the International Prostate Symptom Score (IPSS) and to confirm the absence of prostate cancer suspicion.

For androgenetic alopecia (AGA), coverage is more restricted. OHP generally categorizes hair-loss treatment as a non-covered cosmetic benefit unless a documented medical necessity exception applies. A prior authorization citing psychological comorbidity or post-chemotherapy alopecia may succeed in isolated cases, but routine male-pattern baldness is not a covered indication under standard OHP rules. The Oregon Health Authority outlines cosmetic exclusions in its benefit package under OAR 410-130-0595.

Patients who do obtain OHP coverage for BPH finasteride pay no out-of-pocket copay if they are enrolled in a full OHP CCO (coordinated care organization) plan, because Oregon eliminated most pharmacy copays for OHP members in 2020. That means a qualifying BPH patient could pay $0 per month for generic finasteride after PA approval, compared with $12 cash-pay.

The 5-alpha-reductase inhibitor class, which includes finasteride and dutasteride, is recognized in the American Urological Association 2021 BPH guidelines as a first-line option for men with prostate volume greater than 30 mL. The AUA document states: "Combination therapy with an alpha-blocker and a 5-alpha-reductase inhibitor is recommended for patients at risk for BPH progression." [2]

Compounded Finasteride in Oregon: Legality and Pricing

Compounded finasteride is legal in Oregon when prepared by a state-licensed 503A compounding pharmacy. 503A refers to Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs patient-specific compounding by licensed pharmacists. Oregon Board of Pharmacy licensure requirements align with USP Chapter 795 standards for non-sterile compounding, covering the oral finasteride preparations most commonly dispensed for AGA. The FDA's guidance on 503A compounding outlines the conditions under which compounded drugs may lawfully be prepared for individual patients.

Compounded finasteride typically costs about $45 per month in Oregon from telehealth-affiliated 503A pharmacies in 2026. That price sits well above the $12 generic cash-pay price, so the practical reason to choose compounding is formulation customization rather than cost savings. Common compounded variants include:

• Finasteride 0.5 mg capsules (for patients titrating down from 1 mg due to side effects)
• Finasteride combined with minoxidil in a topical solution or foam for scalp application
• Finasteride 1.25 mg capsules prepared from bulk active pharmaceutical ingredient

Topical finasteride has been investigated as a strategy to reduce systemic DHT suppression and sexual side-effect risk. A 2021 randomized trial (Jimenez-Cauhe et al., N=40) found that topical finasteride 0.25% solution applied daily reduced scalp DHT comparably to oral finasteride while producing less serum DHT suppression, though the study was underpowered for safety endpoints. The FDA has not approved any topical finasteride product, so topical preparations remain compounded and off-label in Oregon.

503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, may not dispense finasteride directly to patients under Oregon law. All compounded finasteride dispensed to Oregon residents must originate from a 503A pharmacy holding an Oregon Board of Pharmacy license or an out-of-state pharmacy holding a non-resident Oregon pharmacy permit. Oregon Board of Pharmacy rules on non-resident pharmacy permits are codified under ORS 689.725.

Private Insurance Coverage for Finasteride in Oregon

Most commercial insurance plans sold on the Oregon health exchange (Cover Oregon / Healthcare.gov marketplace) include finasteride for BPH on Tier 1 or Tier 2 of their formularies, which typically means a $5 to $25 copay per 30-day supply after the deductible period. AGA coverage varies dramatically by plan. A 2022 analysis published in JAMA Dermatology found that fewer than 30% of surveyed commercial formularies covered finasteride 1 mg for AGA without restrictions, reflecting widespread insurer classification of AGA as cosmetic.

Large Oregon-based employers using self-insured plans administered by Moda Health, PacificSource, or Providence Health Plan sometimes include AGA finasteride as a covered benefit under men's health endorsements. Checking the Summary of Benefits and Coverage (SBC) document for your specific plan is the most reliable method. The SBC is required by the ACA and must list drug formulary tier assignments.

Key steps to verify coverage in Oregon:

1. Locate your plan's formulary on the insurer's website or call the member services line.
2. Search for finasteride under generic name (finasteride) and brand names (Propecia, Proscar).
3. Confirm whether the indication (AGA vs. BPH) affects the tier assignment or PA requirement.
4. Ask whether prior authorization requires a specialist (urologist or dermatologist) referral or whether a primary care or telehealth provider prescription is accepted.

Medicare Part D plans covering Oregon beneficiaries generally include finasteride 5 mg for BPH but exclude finasteride 1 mg for AGA under the Part D cosmetic exclusion codified at 42 CFR 423.100. Oregon Medicare Advantage plans follow the same exclusion unless the plan offers a supplemental OTC or men's health benefit.

Telehealth Prescribing of Finasteride in Oregon

Finasteride can be prescribed via telehealth in Oregon. Oregon law permits clinicians licensed in Oregon to prescribe Schedule-uncontrolled drugs like finasteride based on a synchronous (live video) or, under certain circumstances, asynchronous (questionnaire-based) telehealth encounter. Oregon HB 2417 (2021) expanded telehealth prescribing authority and codified parity between telehealth and in-person encounters for most non-controlled medications.

The Oregon Medical Board requires that a valid prescriber-patient relationship be established before issuing a prescription. For finasteride, most telehealth platforms satisfy this by collecting a medical history, reviewing any recent lab work or prostate-specific antigen (PSA) values, and conducting a synchronous video consult. Asynchronous-only platforms operating under a questionnaire model carry regulatory risk in Oregon and should be verified before use.

PSA testing before starting finasteride 5 mg for BPH is recommended by AUA guidelines because finasteride reduces PSA by approximately 50% after 6 months of use, which can mask early prostate cancer detection. Clinicians are advised to double the observed PSA value in patients on finasteride when interpreting cancer-screening results. This applies whether the prescription is issued in-person or via telehealth.

For AGA, baseline PSA is not routinely required at the 1 mg dose in otherwise healthy men, but a review of sexual health history is standard practice before prescribing, given finasteride's FDA-labeled risk of decreased libido, erectile dysfunction, and ejaculatory disorders (incidence 1.3-3.8% in phase III trials). The FDA label for finasteride 1 mg (Propecia) details post-marketing reports of persistent sexual dysfunction after discontinuation, a condition some researchers have termed Post-Finasteride Syndrome (PFS). [3]

Discount Programs and Savings Cards for Finasteride in Oregon

Several cost-reduction pathways exist for Oregon patients paying out-of-pocket for finasteride.

Generic discount cards. GoodRx, RxSaver, and NeedyMeds operate in Oregon without enrollment requirements. Presenting a free GoodRx code at a Fred Meyer, Rite Aid, or Safeway pharmacy in Portland typically brings generic finasteride 1 mg (30 tablets) to $9 to $14. The same codes work at Costco and Walmart pharmacies in Oregon, where base prices are already near the lower bound.

Merck savings program. Merck offers a Propecia savings card for commercially insured patients, reducing out-of-pocket cost to roughly $30 per month for brand Propecia. The card is not valid for OHP Medicaid, Medicare, or uninsured patients. Oregon patients paying cash-pay for the generic rarely benefit from the Merck brand card because the generic is already cheaper even without a discount. Merck's patient assistance and savings card program is administered through the company's own portal and requires proof of commercial insurance.

NeedyMeds patient assistance. For uninsured or underinsured Oregon patients below 200% of the federal poverty level, Merck's Patient Assistance Program may supply brand finasteride at no cost. Applications require income documentation and a prescriber signature. NeedyMeds maintains a searchable database of patient assistance programs including finasteride entries.

340B program. Federally qualified health centers (FQHCs) and rural health clinics in Oregon participating in the 340B drug pricing program can dispense finasteride at acquisition cost, which may fall below $5 per month. Oregon FQHCs include Virginia Garcia Memorial Health Center, Outside In, and Yakima Valley Farm Workers Clinic (southern Oregon locations). Eligibility for 340B pricing requires receiving care at the qualifying entity.

The practical decision framework for an Oregon patient choosing between finasteride pricing options looks like this: If you have OHP Medicaid and a BPH diagnosis, pursue prior authorization first because $0 copay beats every other option. If you are commercially insured for BPH, verify formulary tier and PA requirements before paying cash. If you have AGA and no coverage, start with generic cash-pay at $12 per month using a GoodRx code before considering compounded finasteride at $45 per month, unless your clinician has a specific formulation rationale such as dose titration or topical combination therapy.

Clinical Efficacy: What Oregon Patients Are Actually Paying For

Finasteride received FDA approval for BPH (Proscar 5 mg) in 1992 and for AGA (Propecia 1 mg) in 1997. The key AGA approval relied on two double-blind, placebo-controlled, 12-month studies in men aged 18-41 with mild-to-moderate vertex and anterior mid-scalp hair loss, demonstrating statistically significant increases in hair count (P<0.001 vs. placebo) and patient self-assessment scores. [4]

Kaufman et al. (J Am Acad Dermatol 1998) studied 1,553 men over 48 weeks and found that finasteride 1 mg produced a mean increase of 107 hairs in a 1-inch diameter target area vs. a mean decrease of 13 hairs in the placebo group, representing a 120-hair difference. [1] Discontinuation trials show that roughly 50% of the hair gained is lost within 12 months of stopping the drug, which means the $12 per month cost is effectively ongoing for patients who wish to maintain results.

For BPH, the PLESS trial (Proscar Long-Term Efficacy and Safety Study, N=3,040, 4-year follow-up) showed that finasteride 5 mg reduced the risk of acute urinary retention by 57% and the need for BPH-related surgery by 55% compared with placebo. The PLESS trial results are summarized in the Merck Proscar prescribing information and were published in Urology 1996. [5] Those outcomes inform why Oregon Medicaid covers the BPH indication: preventing surgery is cost-effective even with the PA administrative overhead.

5-alpha-reductase inhibitors also carry a notable oncology consideration. The Prostate Cancer Prevention Trial (PCPT, N=18,882) found that finasteride reduced prostate cancer incidence by 24.8% over 7 years but was associated with a higher proportion of high-grade tumors (Gleason score 7-10) in the treatment arm vs. placebo. [6] The FDA added a label update in 2011 noting this finding. Oregon clinicians prescribing finasteride for BPH or AGA should document this discussion in the patient record.

Side Effects That Affect Adherence and Cost Calculations

Roughly 3-5% of men on finasteride 1 mg discontinue because of sexual side effects (decreased libido, erectile dysfunction, ejaculatory dysfunction) based on phase III data. The original Propecia package insert reported combined sexual dysfunction adverse events in 3.8% of finasteride-treated men vs. 2.1% in the placebo arm during the first year. [3] Post-marketing surveillance has generated case reports of persistent symptoms after discontinuation, though causality and prevalence remain debated in the literature.

A 2020 cohort study by Dyson et al. (BMJ Open, N=2,821 finasteride users) found no statistically significant increase in risk of persistent sexual dysfunction compared with a matched control group, though the authors acknowledged limitations in self-reported outcome capture. [7] Patients considering finasteride therapy should receive this balanced picture before starting.

Gynecomastia occurs in fewer than 1% of users but warrants mention. Liver enzyme elevation is rare and not routinely monitored. Drug interactions are minimal: finasteride is primarily metabolized by CYP3A4, and no dose adjustments are required for common Oregon-prescribed medications.

How Oregon Compares to National Average Pricing

The $12 per month Oregon cash-pay price for generic finasteride 1 mg aligns closely with the national average for states with competitive generic markets. FDA data show that generic competition typically reduces brand drug prices by 80-85% within two years of patent expiration; finasteride's Propecia patent expired in 2013, and there are now more than a dozen FDA-approved generic manufacturers. [8]

Oregon's geographic pricing variation is modest compared with states where pharmacy deserts exist. Rural Oregon counties (Harney, Lake, Wheeler) have fewer competing pharmacies, and cash prices at independent rural pharmacies may run $5 to $8 higher than Portland metro rates. Mail-order pharmacy services, available through most commercial insurers operating in Oregon and directly from online licensed pharmacies, typically offer 90-day supplies at further discount, bringing effective monthly cost to $8 to $10 for a 90-tablet generic order.

The Centers for Medicare and Medicaid Services' data on drug spending confirm that 5-alpha-reductase inhibitors remain among the lower-cost prescription drug classes by per-unit cost, with median Medicaid reimbursement for finasteride 5 mg tablets under $0.10 per tablet in recent years. [9]

Monitoring and Follow-Up Costs Oregon Patients Should Expect

The drug itself costs $12 per month, but starting finasteride involves upstream and ongoing clinical costs that Oregon patients should factor in.

Initial consultation. A telehealth AGA consultation in Oregon runs $40 to $75 for the first visit at most platforms, with annual renewals at $25 to $50. In-person dermatology consultations average $150 to $300 without insurance, though most commercial plans cover a dermatology visit at specialist copay rates.

PSA baseline for BPH. Men starting finasteride 5 mg for BPH should have a PSA drawn before the first dose to establish a baseline. The AUA BPH guideline recommends PSA testing as part of the initial evaluation for all men being considered for 5-alpha-reductase inhibitor therapy. [10] A PSA lab draw costs $15 to $40 cash-pay in Oregon and is covered under most commercial and OHP plans as part of a diagnostic workup.

Annual follow-up. Finasteride for AGA does not require mandatory lab monitoring under current guidelines, but clinicians prescribing via telehealth in Oregon typically schedule a 12-month follow-up visit to assess response and review any adverse effects.

The American Academy of Dermatology's clinical practice guidelines for androgenetic alopecia state that finasteride 1 mg daily is a Grade A, Level I recommendation for male AGA, supported by multiple randomized controlled trials. [11] Oregon patients whose clinicians are unfamiliar with AGA may benefit from a telehealth dermatology consultation to confirm the diagnosis before committing to long-term finasteride therapy.

Practical Checklist for Oregon Patients Starting Finasteride in 2026

Before filling a finasteride prescription in Oregon, confirm the following with your prescriber or pharmacist:

1. Diagnosis documented: BPH (5 mg) or AGA (1 mg) or off-label dose for AGA (0.5 mg, 1.25 mg compounded).
2. Insurance checked: Pull the formulary for your specific Oregon plan, not a national average.
3. OHP PA submitted: If on Oregon Medicaid for BPH, ask whether the prescriber will submit the PA at the time of prescribing.
4. PSA baseline drawn: Required for BPH; recommended for any man over 40 starting finasteride.
5. Discount code ready: GoodRx or RxSaver on your phone before you reach the pharmacy counter.
6. 90-day supply considered: Ask the prescriber to write for 90 days if cash-paying, to reduce per-tablet cost.
7. Side-effect discussion documented: Sexual dysfunction risk and the PFS label update should be in your visit notes.

The FDA's MedWatch program accepts voluntary reports of adverse drug reactions including persistent sexual effects attributed to finasteride. [12] Oregon patients who experience side effects after discontinuing finasteride are encouraged to report through MedWatch and to notify their prescriber.